The Asia Pacific Diabetic Neuropathy Treatment Market would witness market growth of 8.2% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $522.6 million by 2031. The Japan market is registering a CAGR of 7.5% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 8.8% during (2024 - 2031).
Another factor contributing to the growth of the diabetic neuropathy treatment market is the expanding range of treatment options available. Traditionally, the management of diabetic neuropathy has focused on controlling blood sugar levels and relieving symptoms such as pain and discomfort.
Moreover, these approaches remain important, there has been a shift towards a more comprehensive treatment strategy that addresses the underlying causes of nerve damage and aims to prevent or reverse the condition's progression.
India is experiencing a significant increase in diabetes prevalence, driven by factors such as urbanization, sedentary lifestyles, and dietary changes. Based on data from the National Library of Medicine, the estimated number of individuals with diabetes in India in 2019 was 77 million, and this figure is projected to surpass 134 million by 2045. It is projected that approximately 592 million individuals will perish from diabetes by 2035.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $522.6 million by 2031. The Japan market is registering a CAGR of 7.5% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 8.8% during (2024 - 2031).
Another factor contributing to the growth of the diabetic neuropathy treatment market is the expanding range of treatment options available. Traditionally, the management of diabetic neuropathy has focused on controlling blood sugar levels and relieving symptoms such as pain and discomfort.
Moreover, these approaches remain important, there has been a shift towards a more comprehensive treatment strategy that addresses the underlying causes of nerve damage and aims to prevent or reverse the condition's progression.
India is experiencing a significant increase in diabetes prevalence, driven by factors such as urbanization, sedentary lifestyles, and dietary changes. Based on data from the National Library of Medicine, the estimated number of individuals with diabetes in India in 2019 was 77 million, and this figure is projected to surpass 134 million by 2045. It is projected that approximately 592 million individuals will perish from diabetes by 2035.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Distribution Channel- Hospitals Pharmacies
- Retail Pharmacies
- Others
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Antidepressants
- Opioid
- Capsaicin
- Others
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel
Chapter 5. Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class
Chapter 6. Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type
Chapter 7. Asia Pacific Diabetic Neuropathy Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
